EM2006F "Slaying the Hydra: Recurrent Clostridioides difficile infections" (IM GR-062620)
The purpose of this presentation is to acquaint the viewers with recent advances in the treatment and prevention of recurrent Clostridioides difficile infections (rCDI). The presentation will begin with a review of the pathogenesis and epidemiology of rCDI, followed by discussion of newer agents available to treat rCDI (fidaxomicin, bezlotoxumab), and will conclude with remarks on the current state of fecal microbiota transplantation (FMT), generally and at UT Southwestern Medical Center.
Target Audience
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Briefly review the pathogenesis of Clostridioides difficile infections (CDI).
- Discuss the epidemiology and risk factors for recurrent Clostridioides difficile infections (rCDI).
- Review pharmacological/biological interventions to treat and prevent rCDI.
- Provide an overview of fecal microbiota transplantation (FMT) and other interventions designed to favorably alter the host microbiome to prevent rCDI.
Jeffrey Tessier, M.D.
Associate Professor of Internal Medicine
Division of Infectious Disease and Geographic Medicine
Available Credit
- 1.00 AMA
Price
Required Hardware/software
Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome